JP2013526582A5 - - Google Patents

Download PDF

Info

Publication number
JP2013526582A5
JP2013526582A5 JP2013511383A JP2013511383A JP2013526582A5 JP 2013526582 A5 JP2013526582 A5 JP 2013526582A5 JP 2013511383 A JP2013511383 A JP 2013511383A JP 2013511383 A JP2013511383 A JP 2013511383A JP 2013526582 A5 JP2013526582 A5 JP 2013526582A5
Authority
JP
Japan
Prior art keywords
vaccine
cancer
subject
tumor antigen
lung cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013511383A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013526582A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/037327 external-priority patent/WO2011146828A2/en
Publication of JP2013526582A publication Critical patent/JP2013526582A/ja
Publication of JP2013526582A5 publication Critical patent/JP2013526582A5/ja
Pending legal-status Critical Current

Links

JP2013511383A 2010-05-21 2011-05-20 癌治療 Pending JP2013526582A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34733610P 2010-05-21 2010-05-21
US61/347,336 2010-05-21
PCT/US2011/037327 WO2011146828A2 (en) 2010-05-21 2011-05-20 Cancer treatment

Publications (2)

Publication Number Publication Date
JP2013526582A JP2013526582A (ja) 2013-06-24
JP2013526582A5 true JP2013526582A5 (enExample) 2014-07-24

Family

ID=44972662

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013511383A Pending JP2013526582A (ja) 2010-05-21 2011-05-20 癌治療

Country Status (9)

Country Link
US (1) US20110287057A1 (enExample)
EP (1) EP2571522A4 (enExample)
JP (1) JP2013526582A (enExample)
KR (1) KR20130113953A (enExample)
CN (1) CN102883746A (enExample)
AU (1) AU2011255463A1 (enExample)
CA (1) CA2837059A1 (enExample)
IL (1) IL222958A0 (enExample)
WO (1) WO2011146828A2 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475785B2 (en) 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
US8968720B2 (en) 2008-03-20 2015-03-03 University Of Miami Heat shock protein GP96 vaccination and methods of using same
CN102223894A (zh) * 2008-11-21 2011-10-19 迈阿密大学 用于产生粘膜和系统免疫的hiv/siv疫苗
CN103372209B (zh) * 2012-04-24 2014-09-17 中国科学院微生物研究所 gp96蛋白的抗体在制备癌细胞抑制剂中的应用
CN104415335A (zh) * 2013-09-02 2015-03-18 北京中康万达医药科技有限公司 体内个体化系统免疫治疗方法和装置
SG11201705844SA (en) * 2015-02-06 2017-08-30 Heat Biologics Inc Vector co-expressing vaccine and costimulatory molecules
IL293135A (en) 2015-05-13 2022-07-01 Agenus Inc Composition comprising at least two different complexes of a purified stress protein bound to an antigenic peptide
US11666649B2 (en) 2016-10-11 2023-06-06 University Of Miami Vectors and vaccine cells for immunity against Zika virus
CA3058938A1 (en) 2017-04-04 2018-10-11 Heat Biologics, Inc. Intratumoral vaccination
EP3720450A4 (en) * 2017-12-04 2021-07-28 Heat Biologics, Inc. CELL-BASED VACCINE PRODUCTION
JP2021522239A (ja) 2018-04-26 2021-08-30 アジェナス インコーポレイテッド 熱ショックタンパク質結合ペプチド組成物およびその使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020006413A1 (en) * 2000-01-27 2002-01-17 Sobol Robert E. Genetically engineered tumor cell vaccines
EP1667701A4 (en) * 2003-09-26 2007-02-14 Univ Miami TUMOR VACCINE
US8475785B2 (en) * 2008-03-03 2013-07-02 The University Of Miami Allogeneic cancer cell-based immunotherapy
AU2010205782A1 (en) * 2009-01-16 2011-09-08 Agirx Limited Vaccine compositions

Similar Documents

Publication Publication Date Title
JP2013526582A5 (enExample)
Jiang et al. Adoptive CD8+ T cell therapy against cancer: Challenges and opportunities
Fratta et al. The biology of cancer testis antigens: putative function, regulation and therapeutic potential
CY1119941T1 (el) Σταθερα και διαλυτα αντισωματα
WO2009014708A3 (en) Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
HK1250918A1 (zh) 用於胶质母细胞瘤的egfr导向的car疗法
WO2011149909A3 (en) Class i mhc phosphopeptides for cancer immunotherapy and diagnosis
WO2009114085A3 (en) Allogeneic cancer cell-based immunotherapy
Öztorun et al. The outcome of becoming a pediatric burn center in Turkey
HK1201175A1 (en) Antigen presenting cancer vaccine with gamma interferon
BR112014017819A8 (pt) Método de produzir células cancerígenas imunogênicas isoladas, células cancerígenas imunogênicas isoladas, composição imunogênica e vacina autóloga de câncer
WO2009114816A3 (en) Therapeutic cancer antigens
MX2022007779A (es) Tratamiento que involucra celulas efectoras inmunitarias modificadas geneticamente para expresar receptores de antigenos.
WO2011011453A3 (en) Phenotyping tumor-infiltrating leukocytes
CN201886403U (zh) 笔记本电脑散热装置
Vatankulu et al. Does metastatic lymph node SUVmax predict survival in patients with esophageal cancer?
CN201342031Y (zh) 理疗用太空舱
Leung Immunotherapy in acute leukemia
Yang et al. LBA57 MHC-II antigen presentation pathway as a predictive biomarker for sintilimab plus chemotherapy in first-line treatment of locally advanced or metastatic non-squamous non-small cell lung cancer (nsq-NSCLC)
CN202049418U (zh) 一种带支架笔记本电脑
Villarreal et al. 192: IL-33 amplifies memory CD8 T cells and enhances antigen-specific tumor and viral immunity
Uhde et al. Radiation therapy and vaccination against tumor-specific EGFRvIII effectively clears tumors in a murine model of head and neck squamous cell carcinoma
Macagno et al. Perforin-dependent Immune surveillance of ErbB2+ carcinomas in female and male mice
馬維力 et al. Beta-Human Chorionic Gonadotropin Secreting Germinoma Refractory to Multi-Modality Treatment
Öztorun et al. Türkiye’de Çocuk Yanık Merkezi Olmanın Sonuçları